Published in N Engl J Med on July 10, 2014
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis (2016) 1.58
Cerebral aspergillosis in a patient with leprosy and diabetes: a case report. BMC Res Notes (2014) 1.00
Chromoblastomycosis. Clin Microbiol Rev (2017) 0.81
True mycotic aneurysm in a patient with gonadotropinoma after trans-sphenoidal surgery. Surg Neurol Int (2015) 0.75
Combat-Related Pythium aphanidermatum Invasive Wound Infection: Case Report and Discussion of Utility of Molecular Diagnostics. J Clin Microbiol (2015) 0.75
Bronchoscopic instillation of liposomal amphotericin B in management of nonresponding endobronchial mucormycosis. Lung India (2017) 0.75
Cerebral Phaeohyphomycosis: Fulminant Encephalitic Presentation. Indian J Pediatr (2017) 0.75
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Aspergillosis. N Engl J Med (2009) 4.11
The index case for the fungal meningitis outbreak in the United States. N Engl J Med (2012) 3.60
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother (2006) 2.65
Primary central nervous system phaeohyphomycosis: a review of 101 cases. Clin Infect Dis (2003) 2.62
Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol (2002) 2.31
Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med (2012) 2.16
Pathogenesis of mucormycosis. Clin Infect Dis (2012) 2.14
Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med (2012) 2.12
Human fusariosis. Clin Microbiol Infect (2004) 2.02
In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother (1998) 1.98
Fungal infections associated with contaminated methylprednisolone injections. N Engl J Med (2012) 1.90
Utility of (1-3)-β-D-glucan testing for diagnostics and monitoring response to treatment during the multistate outbreak of fungal meningitis and other infections. Clin Infect Dis (2013) 1.82
Cerebral mucormycosis associated with intravenous drug use: three case reports and review. Clin Infect Dis (1994) 1.73
Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother (2008) 1.69
Iatrogenic fungal meningitis: tragedy repeated. Ann Intern Med (2012) 1.54
Infections due to Xylohypha bantiana (Cladosporium trichoides). Rev Infect Dis (1989) 1.45
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Rhinocerebral mucormycosis: predisposing factors. Laryngoscope (1982) 1.38
Clinical presentation of zygomycosis. Clin Microbiol Infect (2009) 1.38
Cerebrospinal fluid (1,3)-β-D-glucan detection as an aid for diagnosis of iatrogenic fungal meningitis. J Clin Microbiol (2013) 1.34
Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis (2009) 1.33
Cerebral phaeohyphomycosis--a cure at what lengths? Lancet Infect Dis (2009) 1.33
Detection of fungal DNA in human body fluids and tissues during a multistate outbreak of fungal meningitis and other infections. Eukaryot Cell (2013) 1.30
Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution. J Clin Microbiol (2012) 1.27
Cross-reactivity of Fusarium spp. in the Aspergillus Galactomannan enzyme-linked immunosorbent assay. J Clin Microbiol (2012) 1.20
Fusarium brain abscess. Case report. J Neurosurg (1983) 1.17
Clinical patterns of Fusarium infections in immunocompromised patients. J Infect (1994) 1.12
Fungal infections of the central nervous system: comparative analysis of risk factors and clinical signs in 57 patients. Neurology (1985) 1.12
Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. Medicine (Baltimore) (2012) 1.10
(1-3)-β-D-glucan in cerebrospinal fluid is useful for the diagnosis of central nervous system fungal infections. Clin Infect Dis (2013) 1.09
A real-time PCR assay for rapid detection and quantification of Exserohilum rostratum, a causative pathogen of fungal meningitis associated with injection of contaminated methylprednisolone. J Clin Microbiol (2013) 1.09
Comparison of the in vitro antifungal activity of free and liposome-encapsulated amphotericin B. Eur J Clin Microbiol Infect Dis (1991) 1.09
Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother (2011) 1.04
Aspergillus meningitis: a rare clinical manifestation of central nervous system aspergillosis. Case report and review of 92 cases. J Infect (2012) 1.02
Cerebral aspergillosis: tissue penetration is the key. Med Mycol (2009) 0.99
Reflections on the approach to treatment of a mycologic disaster. Antimicrob Agents Chemother (2013) 0.96
Aspergillosis of the central nervous system causing subarachnoid hemorrhage from mycotic aneurysm of the basilar artery--case report. Neurol Med Chir (Tokyo) (1990) 0.93
Ochroconis gallopava: a dematiaceous mold causing infections in transplant recipients. Clin Transplant (2011) 0.92
Successful treatment of periodontal mucormycosis: report of a case and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (2010) 0.91
Fungal endophthalmitis in a tertiary care cancer center: a review of 23 cases. Eur J Clin Microbiol Infect Dis (2008) 0.88
What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis? Clin Infect Dis (2013) 0.88
Diagnostic performance of an Aspergillus-specific nested PCR assay in cerebrospinal fluid samples of immunocompromised patients for detection of central nervous system aspergillosis. PLoS One (2013) 0.88
Successful treatment with voriconazole of fungal cerebral abscess due to Cladophialophora bantiana. Clin Neurol Neurosurg (2005) 0.86
Transplant-associated Ochroconis gallopava infections. Transpl Infect Dis (2008) 0.86
Immunotherapy of infections caused by rare filamentous fungi. Clin Microbiol Infect (2011) 0.83
Aspergillus galactomannan antigen for diagnosis and treatment monitoring in cerebral aspergillosis. Prog Transplant (2013) 0.82
Antifungal activity of the local complement system in cerebral aspergillosis. Microbes Infect (2005) 0.79
Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei): case presentation and literature review. J Infect Public Health (2011) 0.78
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2008) 16.51
Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis (2005) 13.97
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med (2007) 10.40
Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med (2007) 5.88
Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis (2012) 5.66
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis (2005) 5.25
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
Recent advances in the management of mucormycosis: from bench to bedside. Clin Infect Dis (2009) 3.77
Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis (2003) 3.70
Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis (2006) 3.57
Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis (2004) 3.10
The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother (2011) 3.04
Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis (2004) 2.98
Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis (2004) 2.89
Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis (2004) 2.81
Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med (2005) 2.79
Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis (2003) 2.73
Infections caused by Scedosporium spp. Clin Microbiol Rev (2008) 2.69
Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis (2008) 2.65
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis (2006) 2.45
Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica (2006) 2.41
Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics (2003) 2.38
Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother (2002) 2.30
Zygomycosis in children: a systematic review and analysis of reported cases. Pediatr Infect Dis J (2007) 2.25
Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med (2015) 2.18
Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis (2011) 2.17
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Pathogenesis of mucormycosis. Clin Infect Dis (2012) 2.14
Glucocorticoids and invasive fungal infections. Lancet (2003) 2.11
Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J (2004) 2.08
Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother (2008) 2.06
Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis (2005) 2.06
Human rhinoviruses. Clin Microbiol Rev (2013) 2.05
Hospitalizations for endemic mycoses: a population-based national study. Clin Infect Dis (2006) 2.02
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood (2010) 1.97
Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis (2012) 1.96
Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol (2003) 1.96
Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation (2006) 1.94
The global challenge of carbapenem-resistant Enterobacteriaceae in transplant recipients and patients with hematologic malignancies. Clin Infect Dis (2014) 1.94
Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol (2012) 1.93
Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infect (2011) 1.90
Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis (2008) 1.88
Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics (2010) 1.86
Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics (2003) 1.86
Socioeconomic disparities in the use and success of fertility treatments: analysis of data from a prospective cohort in the United States. Fertil Steril (2011) 1.85
Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clin Microbiol Rev (2011) 1.82
Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother (2002) 1.79
Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences. Antimicrob Agents Chemother (2007) 1.76
Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob Agents Chemother (2005) 1.75
Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis (2004) 1.74
A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts. Intensive Care Med (2013) 1.74
Diagnosis of invasive mold infection by real-time quantitative PCR. Am J Clin Pathol (2003) 1.73
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother (2002) 1.72
Histoplasmosis-associated cross-reactivity in the BioRad Platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol (2007) 1.70
Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer (2009) 1.69
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.68
Emerging and less common fungal pathogens. Infect Dis Clin North Am (2002) 1.68
Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs (2004) 1.67
Outcomes of central nervous system cryptococcosis vary with host immune function: results from a multi-center, prospective study. J Infect (2010) 1.67
Molecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.67
Breast implant infections: is cefazolin enough? Plast Reconstr Surg (2010) 1.67
A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J (2010) 1.66
A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis (2004) 1.64
Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis (2008) 1.64
Tuberculosis: a benign impostor. AJR Am J Roentgenol (2010) 1.62
The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis (2008) 1.62
Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med Mycol (2005) 1.61
Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother (2002) 1.61
Escherichia coli Pyomyositis: an emerging infectious disease among patients with hematologic malignancies. Clin Infect Dis (2010) 1.60
The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med (2002) 1.60
Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother (2005) 1.59
Geoclimatic influences on invasive aspergillosis after hematopoietic stem cell transplantation. Clin Infect Dis (2010) 1.58
Pulmonary mucormycosis. Semin Respir Crit Care Med (2011) 1.58
Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis (2008) 1.57
A novel application of 1H magnetic resonance spectroscopy: non-invasive identification of spermatogenesis in men with non-obstructive azoospermia. Hum Reprod (2010) 1.56
Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc (2008) 1.56
Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis (2010) 1.55
Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother (2006) 1.55
Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proc Natl Acad Sci U S A (2008) 1.54
Racial differences in vasectomy utilization in the United States: data from the national survey of family growth. Urology (2009) 1.53
Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) (2003) 1.51